The closing price of Fate Therapeutics Inc (NASDAQ: FATE) was $8.12 for the day, down -2.75% from the previous closing price of $8.35. In other words, the price has decreased by -$0.23 from its previous closing price. On the day, 2457065 shares were traded. FATE stock price reached its highest trading level at $8.73 during the session, while it also had its lowest trading level at $7.82.
Ratios:
Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 24, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $115 to $7.
Wedbush Downgraded its Outperform to Neutral on January 06, 2023, whereas the target price for the stock was revised from $42 to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Dulac Edward J III sold 2,447 shares for $7.77 per share. The transaction valued at 19,013 led to the insider holds 101,479 shares of the business.
Dulac Edward J III sold 1,849 shares of FATE for $9,245 on Jan 29 ’24. The Chief Financial Officer now owns 103,926 shares after completing the transaction at $5.00 per share. On Jan 09 ’24, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 14,391 shares for $4.37 each. As a result, the insider received 62,889 and left with 371,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 805.81M and an Enterprise Value of 594.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.68 while its Price-to-Book (P/B) ratio in mrq is 2.17. Its current Enterprise Value per Revenue stands at 9.35 whereas that against EBITDA is -3.45.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.63. The 50-Day Moving Average of the stock is 5.74, while the 200-Day Moving Average is calculated to be 3.87.
Shares Statistics:
FATE traded an average of 2.73M shares per day over the past three months and 2.58M shares per day over the past ten days. A total of 98.63M shares are outstanding, with a floating share count of 86.66M. Insiders hold about 12.68% of the company’s shares, while institutions hold 103.89% stake in the company. Shares short for FATE as of Feb 15, 2024 were 13.31M with a Short Ratio of 4.88, compared to 10.77M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.50% and a Short% of Float of 17.30%.
Earnings Estimates
The firm’s stock currently is rated by 16 analysts. On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.67, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.38 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$1.67 and -$2.62 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.86, with 14 analysts recommending between -$1.47 and -$2.43.
